Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood

Abstract

Background: Neurofilament light (NfL) chain is an established cerebrospinal fluid (CSF) biomarker for neuroaxonal injury. The highly sensitive Quanterix Simoa™ platform is evaluated for NfL measurement in both CSF and blood. There is a need to link historical ELISA data that use bovine NfL to that of Simoa using a recombinant human (rhuman) NfL standard. Results/Methodology: The Simoa NF-light^® Advantage Kit was validated for CSF and qualified for serum and plasma, using both rhuman and bovine NfL calibrators. Matched CSF, serum and plasma samples from 112 multiple sclerosis patients were analyzed using both calibrators. Conclusion: In multiple sclerosis, there is a good correlation between blood and CSF NfL levels. A conversion factor of approximately 5:1 was established between bovine and rhuman NfL calibrators.

Keywords: Alzheimer's disease (AD); Quanterix Simoa™; UmanDiagnostics Nf-Light ELISA (Uman ELISA); amyotrophic lateral sclerosis (ALS); biomarker; cerebrospinal fluid (CSF); multiple sclerosis (MS); neurodegeneration; neurofilament light (NfL) chain.